Dezamizumab  (Synonyms: GSK 2398852; Anti-Serum Amyloid P/SAP Reference Antibody (dezamizumab))

Dezamizumab (GSK 2398852) is a fully humanized clonal IgG1 antibody against serum amyloid P component (SAP) with complement activation and amyloid clearance-inducing activities. Dezamizumab binds to SAP associated with amyloid deposits to form complexes that activate complement and mediate phagocytic clearance, triggering activation of the classical complement pathway. Dezamizumab can be used for the research of systemic amyloidosis^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Serum Amyloid P/SAP

Dezamizumab retains nearly full SAP-binding activity (94% relative to the reference standard) when stored at 2-8 °C, while its SAP-binding activity decreases to 84% and 51% when stored at 25 °C or 40 °C, respectively^[1].
Dezamizumab forms a complex with SAP and binds to C1q; Dezamizumab stored at 2-8 °C maintains nearly complete C1q-binding activity (99% relative to the reference standard), whereas its C1q-binding activity decreases to 75% and 16% when stored at 25 °C or 40 °C, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Dezamizumab mediates clearance of amyloid complexes in humanized murine models of systemic amyloidosis by activating the classical complement pathway and recruiting phagocytic immune cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

325  [NCBI]

P02743

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.18 kDa

1662664-56-3

Liquid

Colorless to light yellow

[Dezamizumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Pentraxin 2/SAP Protein, Human (HEK293, His, HY-P71067) can bind Dezamizumab. The EC₅₀ for this effect is 24.31 ng/mL.

• [1]. Ma J, et al. Novel methods to determine complement activation in human serum induced by the complex of Dezamizumab and serum amyloid P. J Biol Chem. 2021;297(4):101136.  [Content Brief]